Home » Aggrastat Case Series

Aggrastat Case Series

We’ve partnered with Interventional Cardiologists throughout the U.S. to offer you a case series on the contemporary use of AGGRASTAT®  (tirofiban hydrochloride) injection, made accessible as short videos.

The purpose of these videos is to demonstrate a typical use of AGGRASTAT for fellows and those who may not be familiar with the contemporary use of glycoprotein IIb/IIIa inhibitors (GPIs). 

Meet our Presenters

Through long-standing relationships we’ve created with thought-leaders across the U.S. we are excited to offer 3 unique cases presented by Interventional Cardiologists across the U.S.

Click the image or name below to see the 3 unique cases presented by each of physician, or scroll down to view all our content.

Cases Series

Below you will find all cases that are currently available to view. 

Short Infusion Administration in Patient with NSTE-ACS

Intraprocedural Thrombus Formation

Short Infusion Administration in Patient with NSTE-ACS

Clot Develops Intracoronary During PCI

Patient Not Adequately Pre-Treated with Oral Anti-Platelet Therapy

Patient Presenting to ED with NSTEMI

Patient Admitted for NSTEMI with Suspected CTO

Patient Not Pre-Loaded with DAPT prior to PCI

About Aggrastat

AGGRASTAT (tirofiban hydrochloride) is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). 

AGGRASTAT:

  • Offers protection during the delayed onset of the oral P2Y12 agents
  • Has a rapid onset, achieving >90% platelet aggregation inhibition within 10 minutes
  • Is reversible: platelets return to baseline function within 4 to 8 hours of discontinuation of infusion
  • Has no contraindication for patients on hemodialysis
  • Has no drug interactions with oral P2Y12 inhibitors
* Concomitant use of fibrinolytic, anticoagulants and antiplatelet drugs increases the risk of bleeding
Aggrastat Pharmacy Product
Important Safety Information

Indication:

Aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

Contraindications:

  • Known hypersensitivity to any component of Aggrastat®.
  • History of thrombocytopenia with prior exposure to Aggrastat®.
  • Active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within the previous month.

Warnings and Precautions:

  • Aggrastat® can cause serious bleeding. Most bleeding associated with Aggrastat® occurs at the arterial access site for cardiac catheterization. Minimize the use of traumatic or potentially traumatic procedures such as arterial and venous punctures, intramuscular injections, nasotracheal intubation, etc. Concomitant use of fibrinolytics, anticoagulants and antiplatelet drugs increases the risk of bleeding. If bleeding cannot be controlled, discontinue Aggrastat®.
  • Thrombocytopenia: discontinue Aggrastat® and heparin.

Adverse Reactions:

  • Bleeding is the most commonly reported adverse reaction.

For additional information, refer to the full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.FDA.gov/medwatch
or call 1-800-FDA-1088.